Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.
Saved in:
| Title: | Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab. |
|---|---|
| Authors: | Schwarz CW; Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Copenhagen, Denmark., Rasmussen MK; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark., Bertelsen T; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.; Health Institute, Aarhus University, Aarhus, Denmark., Iversen L; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark., Skov L; Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Loft N; Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark. |
| Source: | JAMA dermatology [JAMA Dermatol] 2025 Dec 01; Vol. 161 (12), pp. 1289-1291. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6084 |
|---|---|
| DOI: | 10.1001/jamadermatol.2025.3928 |
